Jak/STAT signaling in human T-cell lymphomas
Jak/STAT signaling in human T-cell lymphomas
批准号:
7906752
负责人:
MARIUSZ A. WASIK
金额:
$24.99万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-03-01 至 2012-07-31
关键词:
BindingBinding ProteinsCell Cycle ProgressionCell LineCell physiologyCellsCodeComplexCytokine ReceptorsDNA MethylationDNA MethyltransferaseDNA Modification MethylasesElementsEpigenetic ProcessGene ExpressionGene SilencingGene TargetingGenesGenomeGoalsHC phosphataseHumanIn VitroInterleukin-15Interleukin-2Interleukin-4Interleukin-9LeadLymphomaLymphomagenesisMalignant - descriptorMalignant NeoplasmsMediatingModelingMusPTPN6 genePathogenesisPathway interactionsPatternPhenotypePhosphotransferasesPlayProcessProgress ReportsProtein FamilyProteinsRelative (related person)RoleSTAT3 geneSTAT5A geneSignal TransductionSignal Transduction PathwaySmall Interfering RNASolidSpecificityStudy SectionT-Cell LymphomaT-Cell TransformationT-LymphocyteTissuesValidationbasecancer cellcancer typecytokinedesignin vivoinhibitor/antagonistmembernovelpromoterreceptorresearch studysmall molecule
中文摘要
描述(由申请方提供):本研究的目的是通过评价人T细胞淋巴瘤,更好地确定异常Jak/STAT信号传导在癌症发病机制中的作用,并了解其机制和后果。积累的实验证据表明,Jak 1/Jak 3/STAT 3/STAT 5信号传导复合物与由细胞因子刺激的几种受体共享的共同g链(gc)相关,这些细胞因子对正常T细胞的活化和成熟至关重要:IL-2、-4、-7、-9、-15和-21,在大的T细胞淋巴瘤亚群的发病机制中起核心作用。编码SHP-1酪氨酸磷酸酶(细胞信号传导的负调节因子)的基因的表观遗传沉默有助于GC相关Jak/STAT途径的异常、持续激活。为了实现本研究的目标,我们将研究:
1. Jak 1和Jak 3活化在恶性T细胞转化中的机制和功能作用。我们将集中在IL-15和IL-21的推定作用,以及Jak 1和Jak 3的相对贡献,T细胞淋巴瘤在体外和Jak 3在体内。
2.通过评估STATs、STAT 5a和STAT 5 b在淋巴瘤发生中的相对贡献,来确定STATs、STAT 5a和STAT 5 b在T细胞转化中的作用。我们将重点关注三种STAT对T细胞淋巴瘤细胞功能和基因表达的影响,以确定直接负责恶性细胞表型的潜在效应蛋白。此外,我们将确定STAT 3诱导的表观遗传基因沉默的靶基因。
3. STAT 3在SHP-1基因表观遗传沉默中的作用及其机制。我们将重点关注STAT 3和DNA甲基转移酶(DNMT)和甲基CpG结合(MBD)蛋白家族成员在SHP-1基因启动子DNA甲基化中的作用。
这项研究应导致更好地了解至少一些亚型的T细胞淋巴瘤的发病机制。此外,它可能导致基于选择性抑制在恶性T细胞中优先利用和/或异常调节的GC相关Jak/STAT信号转导途径的这些元件的淋巴瘤的新疗法。由于STAT 3和STAT 5(在较小程度上)的持续激活已在大范围的恶性肿瘤中得到证实,因此本研究的结果可能会影响对发病机制的理解,并最终影响各种类型癌症的治疗。
英文摘要
DESCRIPTION (provided by applicant): The purpose of this study is to define better the role and understand the mechanisms and consequences of aberrant Jak/STAT signaling in the pathogenesis of cancer by evaluating human T-cell lymphomas. The accumulated experimental evidence indicates that the Jak1/Jak3/STAT3/STAT5 signaling complex associated with the common g chain (gc) shared by several receptors stimulated by cytokines which are critical for activation and maturation of normal T cells: IL-2, -4, -7, -9, -15, and -21, plays a central role in the pathogenesis of a large subset of T-cell lymphomas. Epigenetic silencing of the gene coding for the SHP-1 tyrosine phosphatase, a negative regulator of the cell signaling, contributes to the aberrant, persistent activation of the gc-related Jak/STAT pathways. To accomplish goals of the study we will examine:
1. mechanism and functional role of Jak1 and Jak3 activation in the malignant T-cell transformation. We will focus on the putative role of IL-15 and IL-21 in and the relative contribution of Jak1 and Jak3 to the T-cell lymphomagenesis in vitro and of Jak3 in vivo.
2. role of STATS, STAT5a and STAT5b in the T-cell transformation by evaluating their relative contributions to the lymphomagenesis. We will focus on the impact of the three STATs on the T-cell lymphoma cell function and gene expression to identify potential effector proteins directly responsible for the malignant cell phenotype. In addition, we will identify the target genes of the STAT3-induced epigenetic gene silencing.
3. role of STAT3 in and the mechanisms of the epigenetic silencing of the SHP-1 gene. We will focus on the role of STAT3 and members of the DNA methyltransferase (DNMT) and methyl CpG-binding (MBD) protein families in the DNA methylation of the SHP-1 gene promoter.
This study should result in a better understanding of the pathogenesis of at least some subtypes of T-cell lymphoma. Furthermore, it may lead to novel therapy(ies) for the lymphoma based on selective inhibition of these elements of the gc-associated Jak/STAT signal transduction pathway that are preferentially utilized and/or abberantly regulated in malignant T cells. Because constant activation of STAT3 and, to lesser degree, of STAT5 has been documented in a large spectrum of malignancies, results of this study may impact on understanding pathogenesis and, ultimately, on treatment of various type of cancer.
期刊论文(46)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1016/j.humpath.2006.09.012
发表时间:
2007-03
期刊:
Human pathology
影响因子:
3.3
作者:
[A. Witkiewicz;P. Raghunath;A. Wąsik;J. Junkins-Hopkins;Dan M. Jones;Qian Zhang;N. Odum;M. Wasik]
通讯作者:
A. Witkiewicz;P. Raghunath;A. Wąsik;J. Junkins-Hopkins;Dan M. Jones;Qian Zhang;N. Odum;M. Wasik
IL-15 and IL-17F are differentially regulated and expressed in mycosis fungoides (MF).
IL-15 和 IL-17F 在蕈样肉芽肿 (MF) 中的调节和表达存在差异。
DOI:
10.4161/cc.28256
发表时间:
2014
期刊:
Cell cycle (Georgetown, Tex.)
影响因子:
--
作者:
[Willerslev-Olsen,Andreas, Litvinov,IvanV, Fredholm,SimonM, Petersen,DavidL, Sibbesen,NinaA, Gniadecki,Robert, Zhang,Qian, Bonefeld,CharlotteM, Wasik,MariuszA, Geisler,Carsten, Zhou,Youwen, Woetmann,Anders, Sasseville,Denis, Krejsgaard,]
通讯作者:
Krejsgaard,
Nonmalignant T cells stimulate growth of T-cell lymphoma cells in the presence of bacterial toxins.
在细菌毒素存在的情况下,非恶性 T 细胞会刺激 T 细胞淋巴瘤细胞的生长。
DOI:
10.1182/blood-2006-04-017863
发表时间:
2007
期刊:
Blood
影响因子:
20.3
作者:
[Woetmann,Anders, Lovato,Paola, Eriksen,KarstenW, Krejsgaard,Thorbjørn, Labuda,Tord, Zhang,Qian, Mathiesen,Anne-Merethe, Geisler,Carsten, Svejgaard,Arne, Wasik,MariuszA, Ødum,Niels]
通讯作者:
Ødum,Niels
IL-2R common gamma-chain is epigenetically silenced by nucleophosphin-anaplastic lymphoma kinase (NPM-ALK) and acts as a tumor suppressor by targeting NPM-ALK.
IL-2R 共同 γ 链被核磷蛋白间变性淋巴瘤激酶 (NPM-ALK) 表观遗传沉默,并通过靶向 NPM-ALK 发挥肿瘤抑制因子的作用。
DOI:
10.1073/pnas.1100319108
发表时间:
2011
期刊:
Proceedings of the National Academy of Sciences of the United States of America
影响因子:
11.1
作者:
[Zhang,Qian, Wang,HongYi, Liu,Xiaobin, Bhutani,Gauri, Kantekure,Kanchan, Wasik,Mariusz]
通讯作者:
Wasik,Mariusz
DOI:
--
发表时间:
2014-10
期刊:
Anticancer research
影响因子:
2
作者:
[Simon Fredholm;L. Gjerdrum;Andreas Willerslev-Olsen;D. L. Petersen;I. O. Nielsen;C. Kauczok;M. Wobser;U. Ralfkiaer;C. Bonefeld;M. Wasik;T. Krejsgaard;C. Geisler;E. Ralfkiaer;R. Gniadecki;A. Woetmann;N. Odum]
通讯作者:
Simon Fredholm;L. Gjerdrum;Andreas Willerslev-Olsen;D. L. Petersen;I. O. Nielsen;C. Kauczok;M. Wobser;U. Ralfkiaer;C. Bonefeld;M. Wasik;T. Krejsgaard;C. Geisler;E. Ralfkiaer;R. Gniadecki;A. Woetmann;N. Odum
共 12 条
(m) TOR signaling in EBV-associated lymphomas
-
批准号:7093171
-
项目类别:
-
资助金额:$27.09万
-
财政年份:2005
-
负责人:MARIUSZ A. WASIK
-
依托单位:
(m) TOR signaling in EBV-associated lymphomas
-
批准号:7231674
-
项目类别:
-
资助金额:$26.3万
-
财政年份:2005
-
负责人:MARIUSZ A. WASIK
-
依托单位:
(m) TOR signaling in EBV-associated lymphomas
-
批准号:7075814
-
项目类别:
-
资助金额:$27.74万
-
财政年份:2005
-
负责人:MARIUSZ A. WASIK
-
依托单位:
Dysregulation of STAT3 in ALK-induced oncogenesis
-
批准号:7086206
-
项目类别:
-
资助金额:$29.41万
-
财政年份:2002
-
负责人:MARIUSZ A. WASIK
-
依托单位:
Novel role of STAT3 in NPM/ALK-induced oncogenesis
-
批准号:7989123
-
项目类别:
-
资助金额:$29.04万
-
财政年份:2002
-
负责人:MARIUSZ A. WASIK
-
依托单位:
Novel role of STAT3 in NPM/ALK-induced oncogenesis
-
批准号:7744684
-
项目类别:
-
资助金额:$29.94万
-
财政年份:2002
-
负责人:MARIUSZ A. WASIK
-
依托单位:
Novel role of STAT3 in NPM/ALK-induced oncogenesis
-
批准号:8204454
-
项目类别:
-
资助金额:$29.04万
-
财政年份:2002
-
负责人:MARIUSZ A. WASIK
-
依托单位:
Dysregulation of STAT3 in ALK-induced oncogenesis
-
批准号:6521647
-
项目类别:
-
资助金额:$30.12万
-
财政年份:2002
-
负责人:MARIUSZ A. WASIK
-
依托单位:
Dysregulation of STAT3 in ALK-induced oncogenesis
-
批准号:6914189
-
项目类别:
-
资助金额:$30.12万
-
财政年份:2002
-
负责人:MARIUSZ A. WASIK
-
依托单位:
Novel role of STAT3 in NPM/ALK-induced oncogenesis
-
批准号:7591433
-
项目类别:
-
资助金额:$29.94万
-
财政年份:2002
-
负责人:MARIUSZ A. WASIK
-
依托单位:
Novel role of STAT3 in NPM/ALK-induced oncogenesis
-
批准号:8390441
-
项目类别:
-
资助金额:$27.3万
-
财政年份:2002
-
负责人:MARIUSZ A. WASIK
-
依托单位:
Dysregulation of STAT3 in ALK-induced oncogenesis
-
批准号:6604201
-
项目类别:
-
资助金额:$30.12万
-
财政年份:2002
-
负责人:MARIUSZ A. WASIK
-
依托单位:
Dysregulation of STAT3 in ALK-induced oncogenesis
-
批准号:6771822
-
项目类别:
-
资助金额:$30.12万
-
财政年份:2002
-
负责人:MARIUSZ A. WASIK
-
依托单位:
Jak/STAT signaling in human T-cell lymphomas
-
批准号:7212519
-
项目类别:
-
资助金额:$25.66万
-
财政年份:2001
-
负责人:MARIUSZ A. WASIK
-
依托单位:
Jak/STAT signaling in human T-cell lymphomas
-
批准号:7477661
-
项目类别:
-
资助金额:$24.99万
-
财政年份:2001
-
负责人:MARIUSZ A. WASIK
-
依托单位:
ABERRANT JAK/STAT SIGNALING IN CUTANEOUS T CELL LYMPHOMA
-
批准号:6860159
-
项目类别:
-
资助金额:$24.96万
-
财政年份:2001
-
负责人:MARIUSZ A. WASIK
-
依托单位:
ABERRANT JAK/STAT SIGNALING IN CUTANEOUS T CELL LYMPHOMA
-
批准号:6228819
-
项目类别:
-
资助金额:$24.96万
-
财政年份:2001
-
负责人:MARIUSZ A. WASIK
-
依托单位:
Jak/STAT signaling in human T-cell lymphomas
-
批准号:7667221
-
项目类别:
-
资助金额:$24.99万
-
财政年份:2001
-
负责人:MARIUSZ A. WASIK
-
依托单位:
Jak/STAT signaling in human T-cell lymphomas
-
批准号:7290974
-
项目类别:
-
资助金额:$24.99万
-
财政年份:2001
-
负责人:MARIUSZ A. WASIK
-
依托单位:
ABERRANT JAK/STAT SIGNALING IN CUTANEOUS T CELL LYMPHOMA
-
批准号:6633889
-
项目类别:
-
资助金额:$24.96万
-
财政年份:2001
-
负责人:MARIUSZ A. WASIK
-
依托单位:
海外基金